CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGS BETWEENClinical Investigation Agreement • January 24th, 2022
IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA, headquartered in Via Albertoni 15, 40138 Bologna, tax code: 92038610371, VAT registration number: 02553300373, legally represented by the Director of the U.O.C. Research and Innovation, Dott.ssa Luigia Scudeller, delegated to sign this deed under the resolution no. 28 of 02/02/2018, as confirmed by resolution no. 255 of 31/10/201 (hereinafter the “Entity")
CLINICAL INVESTIGATION AGREEMENT FOR MEDICAL TECHNOLOGY INDUSTRY SPONSORED RESEARCH IN SCOTTISH HEALTH BOARDSClinical Investigation Agreement • May 1st, 2014
WHEREAS the Sponsor is a medical technology company involved in the research, development, manufacture and sale of medical devices for use in humans
Confidential (HEARTWARE LOGO) CLINICAL INVESTIGATION AGREEMENT THIS CLINICAL INVESTIGATION AGREEMENT (this "Agreement") made and effective as of this 17th day of February, 2006 (the "Effective Date"), is by and between Heartware, Inc., a Delaware...Clinical Investigation Agreement • April 30th, 2007 • HeartWare LTD • Florida
CLINICAL INVESTIGATION AGREEMENTClinical Investigation Agreement • July 7th, 2021
This clinical investigation agreement (“Agreement”) is entered into as of the last date of the signature below (“Effective Date”) between
CLINICAL INVESTIGATION AGREEMENT between [Sponsor] and [Hospital] HF and INVEN2 AS Clinical Investigation Title […] Protocol no: […] Investigation Site [Hospital, Department] Principal Investigator Inven2 reference no: […] […]Clinical Investigation Agreement • November 11th, 2020
[The parties can be redefined, for example if a CRO is a contracting party agreeing under its own name or for the Sponsor. In any case the Sponsor is bound to the sponsor’s responsibilities in accordance with ICH GCP and the applicable law. The division of tasks between CRO and Sponsor should be clear and match the separate agreement between Sponsor and CRO.
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGSClinical Investigation Agreement • July 31st, 2020
_ _ _ (indicate whether Director General, CEO, Extraordinary Commissioner, etc.), who has granted _ , (position of signatory) (hereinafter ” ”) with the powers to
Fakultní nemocnice Olomouc, xxxxxxxxxxxxxxxClinical Investigation Agreement • February 24th, 2022
CLINICAL INVESTIGATION AGREEMENT This CLINICAL INVESTIGATIONAGREEMENT (the “Agreement”) is effective on the day of the publishing in accordance with the Act no. 340/2015 Coll. On the Register of Contracts (the “Effective Date”), by and between Fakultní nemocnice Olomouc located at I.P. Pavlova 185/6, 779 00 Olomouc, Czech Republic, represented by Prof. MUDr. Roman Havlík, PhD., director, IČO (Company ID): 00098892 (the “Institution” or “Site”), Pharmaceutical Research Associates CZ, s.r.o., located at Prague 7 Jankovcova 1569/2c Postal Code 170 00 Czech Republic (“PRA”), an affiliate of PHARMACEUTICAL RESEARCHASSOCIATES, INC., located at 4130 Park Lake Avenue, Suite 400 Raleigh North Carolina 27612 US (“PRA INC.”), acting as an independent contractor for NANOBIOTIX S.A., located at 60 rue de Wattignies, 75012 PARIS, France, VAT ID: FR34447521600 (the “Sponsor”). PRA has agreed to accept certain obligations and duties of PRA INC. in respect of the conduct of the clinical trial in Czech
CLINICAL INVESTIGATION AGREEMENTClinical Investigation Agreement • February 22nd, 2022
AGREEMENT (the “Agreement”) is effective from the day of its publication in the Register of Contracts in accordance with the Act on the Register of Contracts (the “Effective Date”), by and between
ContractClinical Investigation Agreement • June 10th, 2021
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGS “A Randomized, Dose-finding and Confirmatory, Double-blind, Placebo-controlled, Parallel-group Multicenter Study with a 2-Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age with Childhood Absence Epilepsy or Juvenile Absence Epilepsy " BETWEEN Fondazione IRCCS Istituto Neurologico Carlo Besta (hereinafter referred to as “Institution”), with registered office at Milano, via Celoria 11Tax Code no. 01668320151 and VAT no. 04376340156, in the person of the General Manager, dott. Paola Lattuada, who signs this deed by virtue of the delegation of the power of signature conferred by the Board of Directors' Resolution. n. V / 37 of 1/7/2019, domiciled for the office at the aforementioned Institute represented by its Legal Representative AND UCB BIOSCIENCES GMBH, headquartered in Alfred-Nobel-Strasse 10, 40789 Monheim, Germany , V
